Cargando…

Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study

INTRODUCTION: Glial fibrillary acidic protein (GFAP) may serve as a serum marker of traumatic brain injury (TBI) that can be used to monitor biochemical changes in patients and gauge the response to treatment. However, the temporal profile of serum GFAP in the acute period of brain injury and the as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jin, Gao, Guoyi, Feng, Junfeng, Jin, Yichao, Wang, Chuanfang, Mao, Qing, Jiang, Jiyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601141/
https://www.ncbi.nlm.nih.gov/pubmed/26455520
http://dx.doi.org/10.1186/s13054-015-1081-8
_version_ 1782394518403809280
author Lei, Jin
Gao, Guoyi
Feng, Junfeng
Jin, Yichao
Wang, Chuanfang
Mao, Qing
Jiang, Jiyao
author_facet Lei, Jin
Gao, Guoyi
Feng, Junfeng
Jin, Yichao
Wang, Chuanfang
Mao, Qing
Jiang, Jiyao
author_sort Lei, Jin
collection PubMed
description INTRODUCTION: Glial fibrillary acidic protein (GFAP) may serve as a serum marker of traumatic brain injury (TBI) that can be used to monitor biochemical changes in patients and gauge the response to treatment. However, the temporal profile of serum GFAP in the acute period of brain injury and the associated utility for outcome prediction has not been elucidated. METHODS: We conducted a prospective longitudinal cohort study of consecutive severe TBI patients in a local tertiary neurotrauma center in Shanghai, China, between March 2011 and September 2014. All patients were monitored and managed with a standardized protocol with inclusion of hypothermia and other intensive care treatments. Serum specimens were collected on admission and then daily for the first 5 days. GFAP levels were measured using enzyme-linked immunosorbent assay techniques. Patient outcome was assessed at 6 months post injury with the Glasgow Outcome Scale and further grouped into death versus survival and unfavorable versus favorable. RESULTS: A total of 67 patients were enrolled in the study. The mean time from injury to admission was 2.6 hours, and the median admission Glasgow Coma Scale score was 6. Compared with healthy subjects, patients with severe TBI had increased GFAP levels on admission and over the subsequent 5 days post injury. Serum GFAP levels showed a gradual reduction from admission to day 3, and then rebounded on day 4 when hypothermia was discontinued with slow rewarming. GFAP levels were significantly higher in patients who died or had an unfavorable outcome across all time points than in those who were alive or had a favorable outcome. Results of receiver operating characteristic curve analysis indicated that serum GFAP at each time point could predict neurological outcome at 6 months. The areas under the curve for GFAP on admission were 0.761 for death and 0.823 for unfavorable outcome, which were higher than those for clinical variables such as age, Glasgow Coma Scale score, and pupil reactions. CONCLUSIONS: Serum GFAP levels on admission and during the first 5 days of injury were increased in patients with severe TBI and were predictive of neurological outcome at 6 months.
format Online
Article
Text
id pubmed-4601141
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46011412015-10-13 Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study Lei, Jin Gao, Guoyi Feng, Junfeng Jin, Yichao Wang, Chuanfang Mao, Qing Jiang, Jiyao Crit Care Research INTRODUCTION: Glial fibrillary acidic protein (GFAP) may serve as a serum marker of traumatic brain injury (TBI) that can be used to monitor biochemical changes in patients and gauge the response to treatment. However, the temporal profile of serum GFAP in the acute period of brain injury and the associated utility for outcome prediction has not been elucidated. METHODS: We conducted a prospective longitudinal cohort study of consecutive severe TBI patients in a local tertiary neurotrauma center in Shanghai, China, between March 2011 and September 2014. All patients were monitored and managed with a standardized protocol with inclusion of hypothermia and other intensive care treatments. Serum specimens were collected on admission and then daily for the first 5 days. GFAP levels were measured using enzyme-linked immunosorbent assay techniques. Patient outcome was assessed at 6 months post injury with the Glasgow Outcome Scale and further grouped into death versus survival and unfavorable versus favorable. RESULTS: A total of 67 patients were enrolled in the study. The mean time from injury to admission was 2.6 hours, and the median admission Glasgow Coma Scale score was 6. Compared with healthy subjects, patients with severe TBI had increased GFAP levels on admission and over the subsequent 5 days post injury. Serum GFAP levels showed a gradual reduction from admission to day 3, and then rebounded on day 4 when hypothermia was discontinued with slow rewarming. GFAP levels were significantly higher in patients who died or had an unfavorable outcome across all time points than in those who were alive or had a favorable outcome. Results of receiver operating characteristic curve analysis indicated that serum GFAP at each time point could predict neurological outcome at 6 months. The areas under the curve for GFAP on admission were 0.761 for death and 0.823 for unfavorable outcome, which were higher than those for clinical variables such as age, Glasgow Coma Scale score, and pupil reactions. CONCLUSIONS: Serum GFAP levels on admission and during the first 5 days of injury were increased in patients with severe TBI and were predictive of neurological outcome at 6 months. BioMed Central 2015-10-12 2015 /pmc/articles/PMC4601141/ /pubmed/26455520 http://dx.doi.org/10.1186/s13054-015-1081-8 Text en © Lei et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lei, Jin
Gao, Guoyi
Feng, Junfeng
Jin, Yichao
Wang, Chuanfang
Mao, Qing
Jiang, Jiyao
Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
title Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
title_full Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
title_fullStr Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
title_full_unstemmed Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
title_short Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
title_sort glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601141/
https://www.ncbi.nlm.nih.gov/pubmed/26455520
http://dx.doi.org/10.1186/s13054-015-1081-8
work_keys_str_mv AT leijin glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy
AT gaoguoyi glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy
AT fengjunfeng glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy
AT jinyichao glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy
AT wangchuanfang glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy
AT maoqing glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy
AT jiangjiyao glialfibrillaryacidicproteinasabiomarkerinseveretraumaticbraininjurypatientsaprospectivecohortstudy